||Assessment process complete
||For the treatment of CDI also known as CDAD in adult patients. Rapid Review
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
||Full Pharmacoeconomic Evaluation Recommended.
|Full pharmacoeconomic assessment commissioned by HSE
|NCPE assessment completed
|NCPE assessment outcome
Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013 www.hpsc.ie).